Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 7/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.37 |
| ▸ | PPARD | Q03181 | 2/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5632474 | 1.00 | FFAR1 (0.52) | FFAR1FFAR4CHRM2CHRM1PPARD | |
| SCHEMBL5486388 | 0.87 | FFAR1 (0.50) | FFAR1FFAR4CHRM2CHRM1PPARD | |
| SCHEMBL5480906 | 0.87 | FFAR1 (0.50) | FFAR1FFAR4CHRM2CHRM1PPARD | |
| SCHEMBL5480902 | 0.87 | FFAR1 (0.50) | FFAR1FFAR4CHRM2CHRM1PPARD | |
| SCHEMBL5484146 | 0.85 | FFAR1 (0.47) | FFAR1FFAR4PPARA | |
| SCHEMBL5634911 | 0.84 | FFAR1 (0.54) | FFAR1FFAR4CHRM2CHRM1PPARD | |
| SCHEMBL5634910 | 0.84 | FFAR1 (0.54) | FFAR1FFAR4CHRM2CHRM1PPARD | |
| SCHEMBL9440070 | 0.80 | FFAR1 (0.45) | FFAR1FFAR4CHRM2CHRM1PPARD | |
| SCHEMBL5634669 | 0.79 | FFAR1 (0.50) | FFAR1FFAR4CHRM2CHRM1PPARD | |
| SCHEMBL5634667 | 0.79 | FFAR1 (0.50) | FFAR1FFAR4CHRM2CHRM1PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220877-B2 | Compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2007-05-22 | — | — | US | disclosed |
| EP-1438283-A1 | DICARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE | NOVO NORDISK A/S (DK) | 2004-07-21 | — | — | EP | disclosed |
| US-20030109579-A1 | Novel compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC | 2003-06-12 | — | — | US | disclosed |
| WO-2003033453-A1 | DICARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THERAPEUTICAL USE | NOVO NORDISK A/S (DK) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109579-A1 | Novel compounds, their preparation and use | PPARG, PPARA, PPARD | FFAR1 33/4885FFAR4 36/4885CHRM2 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.